Last updated: April 23, 2026
Who Supplies Haloperidol Decanoate?
Haloperidol decanoate is a branded and generic long-acting injectable (LAI) antipsychotic. The practical “supplier” set for investors and procurement teams splits into two layers: (1) manufacturers that produce the drug product (drug-in-a-vial) and (2) the upstream API and excipient supply chain. The supplier landscape is product- and market-specific because approvals, packaging formats, and labeling differ by jurisdiction and strength.
Which companies supply Haloperidol Decanoate drug product?
In practice, most “suppliers” come from a limited number of global sterile injectables players and from regional generic manufacturers that hold a local marketing authorization and finished-goods supply agreements.
Below is a structured supplier view by business function. (Finished dose strengths and package sizes vary by market.)
Drug product manufacturers (sterile injectable)
- Generic and regional sterile injectable manufacturers that file ANDAs/MAAs for haloperidol decanoate presentations
- License holders that market under their own label in a given country while sourcing the finished product from a contract manufacturer
Contract manufacturing and sterile fill-finish
- Companies that provide sterile fill-finish for LAI injectables (vial filling, lyophilization if applicable, sterile filtration, terminal sterilization, visual inspection, packaging)
- Contract sterile services for generic injectable portfolios
API suppliers (upstream)
- API manufacturers producing haloperidol decanoate active substance under cGMP for downstream sterile injectables makers
- Intermediates and esterification supply chain may be sourced from specialized chemical producers depending on the drug master file structure
Excipients and packaging
- Solvent and vehicle suppliers used in the oil-based injectable formulation
- Primary packaging suppliers for vials/closures and secondary packaging for distribution requirements
Where do supplier lists typically get validated?
For procurement and patent-landscape diligence, supplier “proof” typically comes from:
- FDA Orange Book listing for US products that identifies the approved manufacturers for each dosage form and strength (ANDA holders and NDA holders by listing)
- EMA/European national registers for European authorization holders
- National labeling databases (Canada, UK, Australia, etc.) for marketing authorization holders and manufacturers
- Drug master file (DMF) referencing for API manufacturing sites (commonly reflected indirectly through approvals and inspection histories)
Supplier Landscape: How to Map “Suppliers” to Commercial Responsibility
Are “suppliers” the marketing authorization holder or the actual manufacturer?
They can differ. In most jurisdictions, the supply chain splits into:
- Marketing authorization holder (MAH): entity responsible for product quality and regulatory compliance in-country
- Manufacturing site: plants listed for drug substance and drug product steps
- Distributor: logistics and commercialization entity (sometimes the MAH, sometimes not)
For LAIs, even when a brand or label changes, the sterile manufacturing site often remains tied to a specific fill-finish and release operation, which is what impacts:
- supply risk
- inspection outcomes
- batch release timelines
What determines which suppliers appear for haloperidol decanoate in a given market?
- Formulation and strength (standard LAI presentations; oil vehicle)
- Packaging configuration (vial size and unit count)
- Regulatory filing history (local ANDA/MAA lineage)
- Contract manufacturing capacity and sterile block availability
Market-Specific Supplier Mapping (What Procurement Teams Actually Use)
United States
US “supplier” identification is anchored to:
- FDA Orange Book listings for haloperidol decanoate products, which name the approved application holder and provide listing-level references.
Europe
EU supplier visibility typically relies on:
- the EMA product database and national submission systems for MAH and manufacturing site listings
United Kingdom, Canada, Australia
These jurisdictions use similar approaches through:
- national drug product registers
- marketing authorization documentation that lists manufacturer sites for release
Key Takeaways
- “Suppliers” for haloperidol decanoate depend on the market, because regulatory listings name different roles (MAH vs manufacturer vs distributor).
- For accurate supplier identification, validation must use jurisdiction-specific approval registers (FDA Orange Book in the US; EMA/national registers in Europe).
- In LAIs, procurement due diligence should separate finished drug product manufacturing sites (sterile fill-finish and release) from API sourcing, because the supply risk profile differs.
FAQs
1) Who makes haloperidol decanoate?
It is produced by companies that hold regulatory approval for specific market presentations and manufacture sterile injectable drug product under cGMP at listed sites, with upstream API sourced from approved API manufacturers under drug substance controls.
2) Is the supplier the same worldwide?
No. Supplier identification varies by country based on which company holds the authorization for that product presentation and which manufacturing site is listed for drug product release.
3) How can companies confirm the true manufacturing supplier?
By checking jurisdiction-specific product registers/approval databases that list manufacturing sites and application holders tied to the approved product presentation.
4) Why does the supplier change when the label changes?
Because different MAHs can market the same presentation or different presentations can be filed under different applications that use distinct manufacturing and release sites.
5) What matters most for supply continuity?
Finished drug product manufacturing site capacity (sterile fill-finish and release) and historical regulatory inspection outcomes tied to those listed sites.
References
[1] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] EMA. Medicines Product Information and European public assessment information. European Medicines Agency. https://www.ema.europa.eu/en/medicines
